NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
Nanobiotix S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$21.08−0.22 (-1.03%)
Close on Oct 19, 2026
Share price
−$4.52 (−17.66%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Nanobiotix S.A. reported revenue of €32.59M for fiscal 2025. Free cash flow was -€33.96M.
Revenue
€32.59M
FY2025
Operating income
-€10.82M
FY2025
Free cash flow
-€33.96M
FY2025
EPS, diluted
-0.50 EUR
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €32.59M
- Net income
- -€23.96M
- EPS, diluted
- -0.50 EUR
- Free cash flow
- -€33.96M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Nine years at a glance
Fiscal years 2017 to 2025, EUR
Revenue
€32.59M
Operating income
-€10.82M
Net income
-€23.96M
EPS, diluted
-0.50 EUR
Free cash flow
-€33.96M
Reported period